样本部位影响肾细胞癌的RNA生物标志物
研究基于1132例转移性透明细胞肾细胞癌(ccRCC)患者数据,评估组织部位对转录组生物标志物临床相关性的影响。发现基因表达按组织部位存在显著且可重复的差异,且分子组织簇与无进展生存期(PFS)的关联因原发灶或转移灶而异。结果表明组织部位可能是生物标志物分析中的相关混杂因素。
要点
- 基因表达按组织部位存在显著且可重复的差异。
- IMmotion151中MTC2-转移灶与舒尼替尼更好PFS相关(HR 3.39),而MTC2-原发灶无此关联。
- CheckMate试验中JAVELIN-转移灶与ICI更好PFS相关(HR 0.77),JAVELIN-原发灶无此关联。
核心结论
- 组织部位可能是生物标志物分析中的相关混杂因素。
研究设计与样本
- 评估1132例既往研究(IMmotion151和CheckMate-009、-010、-025)中接受免疫检查点抑制剂(ICI)治疗的转移性ccRCC患者数据。
主要发现
- IMmotion151中,MTC2-转移灶与舒尼替尼更好PFS显著相关(HR 3.39,95%CI 1.32-8.69;p=0.01),而MTC2-原发灶无显著关联(HR 0.95,95%CI 0.65-1.38;p=0.80;交互作用p=0.02)。
- CheckMate试验中,JAVELIN-转移灶与ICI更好PFS相关(HR 0.77,95%CI 0.62-0.97;p=0.03),而JAVELIN-原发灶无显著关联(HR 1.04,95%CI 0.91-1.19;p=0.56;交互作用p=0.02)。
关键数值与推荐
- IMmotion151中MTC2-转移灶对比MTC2-原发灶与舒尼替尼PFS的交互作用p=0.02。
- CheckMate试验中JAVELIN-转移灶对比JAVELIN-原发灶与ICI PFS的交互作用p=0.02。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunotherapy (ICIs) remains a mainstay for treatment of advanced clear-cell renal cell carcinoma (ccRCC). Biomarker analyses have demonstrated that gene expression profiles are associated with regimen-specific outcomes. These transcriptomic analyses used mixed sample cohorts (primary and metastatic tumor specimens) and it is unknown whether the clinical relevance of transcriptomic signatures is impacted by tissue site. We evaluated data for 1132 patients with metastatic ccRCC treated with ICI in prior studies (IMmotion151 and CheckMate-009, -010, and -025). We identified significant and reproducible differences in gene expression by tissue site. We tested the association between previously described molecular tissue clusters (MTCs) by tissue site (MTC1-primary and MTC1-metastasis) and progression-free survival (PFS) and objective response to systemic therapy. In IMmotion151, MTC2-metastasis was significantly associated with better PFS on sunitinib (hazard ratio [HR] 3.39, 95% confidence interval [CI] 1.32-8.69; p = 0.01) in comparison to MTC2-primary (HR 0.95, 95% CI 0.65-1.38; p = 0.80; pinteraction = 0.02). Evaluation of known RNA signatures in the CheckMate trials revealed that JAVELIN-metastasis was associated with better PFS on ICI (HR 0.77, 95% CI 0.62-0.97; p = 0.03) in comparison to JAVELIN-primary (HR 1.04, 95% CI 0.91-1.19; p = 0.56; pinteraction = 0.02). These results indicate that tissue site may be a relevant confounder in biomarker analyses.
引用
- Eismann L, Xie AX, Tang C, et al. Sample Site Impacts RNA Biomarkers for Renal Cell Carcinoma. Eur Urol. 2024. PMID: 39358058. doi:10.1016/j.eururo.2024.09.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。